Pengaruh CYP2D6 terhadap Kegagalan Terapi Primakuin pada Malaria Vivaks

Kamalia Layal; Anggi Gayatri

doi:10.32502/sm.v5i1.1419

Pengaruh CYP2D6 terhadap Kegagalan Terapi Primakuin pada Malaria Vivaks

Kamalia Layal, Anggi Gayatri

Abstract

Malaria vivaks merupakan salah satu jenis malaria yang sering dialami oleh manusia. Infeksi Plasmodium vivaks adalah penyebab dari malaria ini. Spesies ini berbeda dengan plasmodium lainnya karena mempunyai stadium dorman dalam hati manusia yang disebut hipnozoit. Primakuin merupakan satu-satunya obat antimalaria yang mampu mengeliminasi stadium ini. Namun akibat sering timbulnya kegagalan dalam terapi malaria vivaks, mengakibatkan kekambuhan. Kegagalan ini dapat disebabkan oleh berbagai faktor, salah satunya adalah rendahnya aktivitas isoenzim sitokrom P450 yaitu CYP2D6.

Keywords

CYP2D6, malaria vivaks, primakuin

Full Text:

PDF

References

Hulden L, Hulden L. Activation of the hypnozoit: a part of Plasmodium vivax life cycle and survival. Malar J 2011; 10:90

Sutanto I, Tjahjono B, Basri H, Taylor WR, Putri FA, Meilia RA, et al. Randomized, open label trial of primaquine against vivax malaria relapse in Indonesia. AAC 2013;57:1128-35

Fernando D, Rodrigo C, Rajapakse S. Primaquine in vivax malaria: an update and review on management issues. Malar J 2011;10:351

Galappaththy GNL, Tharyan P, Kirubakaran R. Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine (Review). The Cochrane Library 2013;10

Naing C, Whittaker MA, Wai VN, Mak JW. Is Plasmodium vivax malaria a severe malaria?: A systematic review and meta-analysis. Plos Negl Trop Dis 2014;8(8):e3071

Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected and not benign. Am. J. Trop. Med. Hyg. 2007;77(6):79-87

Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 2001;64:97-106

Vinetz JM, Clain J, Bounkeua V, Eastman RT, Fidock D. Chemotherapy of malaria. In: Brunton L, Chabner B, Knollman B, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 12th ed. New York: Mc Graw Hill; 2011. p.1383-418. 9. Ingram RJH, Darusallam CC, Soebianto S, Noviyanti R, Baird JK. The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea. Malar J 2014;13:488

Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar J 2014;13:418

Baird JK. Effectiveness of Antimalarial Drugs. N Engl J Med 2005;352:1565-77

Davanco MG, Aguiar ACC, Santos LA, Padilha EC, Campos ML, Andrade CR, et al. Evaluation of antimalarial activity and toxicity of new primaquine prodrug. Plos one 2014;9(8):e105217

Fasinu PS, Tekwani BL, Nanayakkara D, Avula B, Herath HMTB, Wang YH, et al. Enatioselective metabolisme of primaquine by human CYP2D6. Malar J 2014; 13:507

Myint HY, Berman J, Walker L, Pybus B, Melendez V, Baird JK, et al. Review: Improving the therapeutic index of 8-aminoquinolines by the use of drug combination: Review of the literature and proposal for future investigations. Am. J. Trop. Med. Hyg 2011;85(6):1010-14

Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, et al. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar J 2013;12:212. 16. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magil AJ. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 2006;75:402-15

Pinto N, Dolan ME. Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab 2011;12(5):487-497

Bennet JW, Pybus BS. Yadava A, Tosh D, Causa JC. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med. 2013; 369:14

DOI: https://doi.org/10.32502/sm.v5i1.1419